Evaluation of sequential FDG-PET/CT for monitoring bone metastasis of breast cancer during therapy: Correlation between morphological and metabolic changes with tumor markers

Annals of Nuclear Medicine

Volumn 26, Issue 5, 2012, Pages 426-435

  Katayama, Takashi ^a   Kubota, Kazunori ^a   MacHida, Youichi ^a   Toriihara, Akira ^a   Shibuya, Hitoshi ^a  

^a TOKYO MEDICAL AND DENTAL UNIVERSITY HOSPITAL   (Japan)

Author keywords

Bone metastasis; Breast; FDG PET CT; Serum tumor markers

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; FLUORODEOXYGLUCOSE F 18; TRASTUZUMAB; TUMOR MARKER;

ADULT; AGED; ARTICLE; BIOLOGICAL MONITORING; BONE METASTASIS; BRAIN METASTASIS; BREAST CANCER; CALCULATION; CANCER CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CHI SQUARE TEST; CLINICAL ARTICLE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE COURSE; HUMAN; KAPPA STATISTICS; PRIORITY JOURNAL; SCLEROSIS; SEQUENTIAL ANALYSIS; BONE NEOPLASMS; BREAST TUMOR; COMPUTER ASSISTED TOMOGRAPHY; FEMALE; METABOLISM; MIDDLE AGED; PATHOLOGY; POSITRON EMISSION TOMOGRAPHY; RETROSPECTIVE STUDY; SECONDARY; TIME FACTOR;

ADULT; AGED; BIOMARKERS, TUMOR; BONE NEOPLASMS; BREAST NEOPLASMS; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; MIDDLE AGED; POSITRON-EMISSION TOMOGRAPHY; RETROSPECTIVE STUDIES; TIME FACTORS; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84862657387     PISSN: 09147187     EISSN: 18646433     Source Type: Journal    
DOI: 10.1007/s12149-012-0595-2     Document Type: Article

References (23)

1. Kohno N, Aogi K, Minami H, Nakamura S, Asaga T, Iino Y, et al. Zoledronic acid significantly reduces skeletal complications compared with placebo in Japanese women with bone metastases from breast cancer: a randomized, placebo-controlled trial. J Clin Oncol. 2005;23:3314-21.
2. Dürr HR, Müller PE, Lenz T, Baur A, Jansson V, Refior HJ. Surgical treatment of bone metastases in patients with breast cancer. Clin Orthop Relat Res. 2002;396:191-6. (Pubitemid 34207971)
3. Tong D, Gillick L, Hendrickson FR. The palliation of symptomatic osseous metastases: final results of the Study by the Radiation Therapy Oncology Group. Cancer. 1982;50:893-9. (Pubitemid 12047122)
4. Blitzer PH. Reanalysis of the RTOG study of the palliation of symptomatic osseous metastasis. Cancer. 1985;55:1468-72. (Pubitemid 15140678)
5. Hillner BE, Ingle JN, Chlebowski RT, Gralow J, Yee GC, Janjan NA, et al. American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer. J Clin Oncol. 2003;21:4042-57. (Pubitemid 46606220)
6. Du Y, Cullum I, Illidge TM, Ell PJ. Fusion of metabolic function and morphology: sequential [18F]fluorodeoxyglucose positronemission tomography/computed tomography studies yield new insights into the natural history of bone metastases in breast cancer. J Clin Oncol. 2007;25:3440-7. (Pubitemid 47310881)
7. Hamaoka T, Madewell JE, Podoloff DA, Hortobagyi GN, Ueno NT. Bone imaging in metastatic breast cancer. J Clin Oncol. 2004;22:2942-53. (Pubitemid 41079914)
8. Tateishi U, Gamez C, Dawood S, Yeung HW, Cristofanilli M, Macapinlac HA. Bone metastases in patients with metastatic breast cancer: morphologic and metabolic monitoring of response to systemic therapy with integrated PET/CT. Radiology. 2008;247:189-96.
9. Bellamy EA, Nicholas D, Ward M, Coombes RC, Powles TJ, Husband JE. Comparison of computed tomography and conventional radiology in the assessment of treatment response of lytic bony metastases in patients with carcinoma of the breast. Clin Radiol. 1987;38:351-5. (Pubitemid 17101596)
10. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228-47.
11. Wahl RL, Jacene H, Kasamon Y, Lodge MA. From RECIST to PERCIST: evolving considerations for PET response criteria in solid tumors. J Nucl Med. 2009;50:122S-50S.
12. Juweid ME, Cheson BD. Positron-emission tomography and assessment of cancer therapy. N Engl J Med. 2006;354:496-507. (Pubitemid 43200300)
13. Young H, Baum R, Cremerius U, HerHolz K, Hoekstra O, Lammertsma AA, et al. Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group. Eur J Cancer. 1999;35: 1773-82. (Pubitemid 29512308)
14. Ludbrook J. Statistical techniques for comparing measurers and methods of measurement: a critical review. Clin Exp Pharmacol Physiol. 2002;29:527-36. (Pubitemid 34639322)
15. Gönen M, Panageas KS, Larson SM. Statistical issues in analysis of diagnostic imaging experiments with multiple observations per patient. Radiology. 2001;221:763-7. (Pubitemid 33101770)
16. Amir E, Whyne C, Freedman OC, Fralick M, Kumar R, Hardisty M, et al. Radiological changes following second-line zoledronic acid treatment in breast cancer patients with bone metastases. Clin Exp Metastasis. 2009;26:479-84.
17. Kouloulias V, Matsopoulos G, Kouvaris J, Dardoufas C, Bottomley A, Varela M, et al. Radiotherapy in conjunction with intravenous infusion of 180 mg of disodium pamidronate in management of osteolytic metastases from breast cancer: clinical evaluation, biochemical markers, quality of life, and monitoring of recalcification using assessments of gray-level histogram in plain radiographs. Int J Radiat Oncol Biol Phys. 2003;57:143-57. (Pubitemid 36959750)
18. Yamaguchi T, Tamai K, Yamato M, Honma K, Ueda Y, Saotome K. Intertrabecular pattern of tumors metastatic to bone. Cancer. 1996;78:1388-94. (Pubitemid 26317858)
19. Yamaguchi T. Intertrabecular vertebral metastases: metastases only detectable on MR imaging. Semin Musculoskelet Radiol. 2001;5:171-5. (Pubitemid 32705950)
20. Cook GJ, Houston S, Rubens R, Maisey MN, Fogelman I. Detection of bone metastases in breast cancer by 18FDG PET: differing metabolic activity in osteoblastic and osteolytic lesions. J Clin Oncol. 1998;16:3375-9. (Pubitemid 28481635)
21. Uematsu T, Yuen S, Yukisawa S, Aramaki T, Morimoto N, Endo M. Comparison of FDG PET and SPECT for detection of bone metastases in breast cancer. Am J Roentgenol. 2005;184: 1266-73. (Pubitemid 43821911)
22. Nakai T, Okuyama C, Kubota T, Yamada K, Ushijima Y, Taniike K, et al. Pitfalls of FDG-PET for the diagnosis of osteoblastic bone metastases in patients with breast cancer. Eur J Nucl Med Mol Imaging. 2005;32:1253-8. (Pubitemid 41598715)
23. Abe K, Sasaki M, Kuwabara Y, Koga H, Baba S, Hayashi K, et al. Comparison of 18FDG-PET with 99mTc-HMDP scintigraphy for the detection of bone metastases in patients with breast cancer. Ann Nucl Med. 2005;19:573-9. (Pubitemid 43161842)